Dermira, Inc. (DERM) Stock: A Biotech Stock That’s Seeing Declines


Dermira, Inc. (DERM) is working its way for to the bottom in the market in today’s trading session. The company, one that is focused on the biotechnology space, is presently priced at $5.31 after tumbling -6.68% so far in today’s session. When it comes to biotech stocks, there are a number of aspects that have the ability to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines surrounding DERM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-14-19 10:28AM Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
Oct-10-19 09:57AM Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
08:30AM Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
Oct-09-19 08:30AM Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Oct-08-19 04:05PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nonetheless, when making an investing decision, prospective investors should focus on far more than news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happening in regard to Dermira, Inc..

Trends That We’ve Seen From DERM

While a move down on a single session, like what we’re seeing from Dermira, Inc. may make some investors upset, a single session decline by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally smart to look at trends experienced by the stock further out than a single trading day. As it relates to DERM, here are the movements that we’ve seen:

  • Past Seven Days – In the last 7 days, DERM has produced a price change amounting to -12.95%.
  • Past Month – The monthly returns from Dermira, Inc. has been -40.74%.
  • Past Three Months – Throughout the last 3 months, the company has produced a return of -38.75%
  • Past Six Months – Over the previous 6 months, we have seen a performance that equates to -53.79% from the company.
  • YTD – Since the close of last year DERM has resulted in a ROI of -26.15%.
  • Full Year – Finally, in the last full year, we’ve seen performance amounting to -52.33% out of DERM. Over this period, the stock has traded at a high price of -65.70% and a low price of 0.25%.

Rations That You Should Consider

Looking at a few key ratios having to do with a company can give traders an understanding of just how dangerous and/or rewarding a stock pick may be. Below are a few of the important ratios to consider when looking at DERM.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is going to tumble. Across the sector, biotechnology stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Dermira, Inc., it’s short ratio comes to 8.31.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay for its debts when they mature with only quick assets or current assets. In the biotech sector, many companies rely on the continuation of support from investors, the current and quick ratios can look upsetting. Nonetheless, several better companies in the biotech sector do have strong current and quick ratios. As far as DERM, the quick and current ratios add up to 8.10 and 8.40 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. In this case, that ratio equates to 1.21.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a biotechnology stock, this is a very important ratio to think about. When it comes to DERM, the cash to share value comes to 6.02.

How Analysts Feel About Dermira, Inc.

While it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their analysis to validate your own opinions when it comes to making investment decisions in the biotechnology space. Here are the recent moves that we’ve seen from analysts with regard to DERM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-06-19 Upgrade Mizuho Neutral → Buy $17 → $14
Mar-25-19 Reiterated Needham Buy $16 → $22
Feb-22-19 Initiated SVB Leerink Outperform $20
Feb-14-19 Initiated H.C. Wainwright Buy $13
Jan-17-19 Upgrade Raymond James Underperform → Mkt Perform

What Institutions And Insiders Think Of Dermira, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in DERM, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own 80.11% of DERM. On the other hand, it is worth mentioning that institutional ownership has seen a move in the amount of 0.78% throughout the past quarter.
  • Investors On The Inside – When it comes to insiders, those close to the company currently own 0.60% of the company. Insider ownership of the company has seen a move of -1.82% in the past quarter.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 54.03M shares of Dermira, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, DERM has a float of 53.90M.

It’s also important to follow the short percentage of the float. After all, if a large portion of the float available for trading is shorted, the overall feeling in the market is that the stock is going to lose value. When it comes to DERM, the percentage of the float that is currently being sold short is 10.07%. In general, high short percent of the float would be considered to be anything over 40%. In my research, I have calculated that any short ratio over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from DERM in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, analysts expect that Dermira, Inc. will create earnings per diluted share in the amount of -4.68, with -1.34 being announced in the next financial report. Although this information is not based on earnings, since we are talking on the topic of Wall Street analysts, DERM is currently rated a 1.90 on a scale from 1 to 5 where 1 is the poorest Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last half decade, Dermira, Inc. has generated a movement in sales volume that adds up to 0. Earnings per diluted share over the last half decade have seen movement in the amount of -39.30%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is often represented in today’s society, Dermira, Inc. has generated a change in earnings that amounts to 41.80%. DERM has also seen a change in terms of revenue that totals 70.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was made by a human and human beings actually play an important part in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here